and report good quarter everyone. hope afternoon, fiscal adjusted you're pleased and exceeded We our to all sales that the Robert, and safe am fourth for Thanks, net XXXX expectations. healthy. I EPS
quarter, of and fourth diluted million per gross $XXX share. of XX% EPS adjusted margin adjusted the we net of $X.XX with For reported sales an
launched For financial the full of new we on including our our six solid products year, XX Numbrino, our in the quarter. the new own and fourth our well XXXX the reflects launch products clinical that trials. as XX made were based the of as NDA launched fiscal approved products, of products performance operational included strong year in-line efficiency products, contributions to XX improvements first
a in Our employees, medications acknowledgment. production of deserve our especially those involved special and development the
million months to team efforts ended offering, XXXX continue marked structure business. and and to actually Over the set and capital down improved pandemic, XX last management We the of during safety from our despite and recognition completing last facility our was do. successfully important including their commitment, Fiscal by several record is pay $XX added plants at key strengthen experienced in debt and they levels this, our our tenured increased, quarter Seymour the also notes the convertible output those strains $XXX XXXX. pandemic. an work from areas to the employees' of required our June diligence our measures months million production for of of our million in the has $XXX a by to testament last XX, production working This
development our improved expected of initiatives internal cash fiscal new to enhance strategic capital stood value rigor our and and the R&D Notably, we $XXX progress those at also But our various position, also implemented million of of discipline which added year. at alliances. and the in the pipeline, many relationships by tremendously the end existing programs. working to future We of part we further establishing efforts quality expanding and
the all additional on several company overcame just of I'll beginning the these details moment. year first, guidance. for of of a what outlook challenge discuss to in prior the result But in a briefly history, want managed and to As in fiscal the developing most updates of of our and opportunities the coming some of and company's our XXXX. considered I Levothyroxine, we this, profitable provide losing product the
year to First, fiscal with X quarter. year of we launched respect full gross as products top the products new including we as the in launch in benefit from to continuing expect and margin, XX launched the a of our fourth line XXXX, we well from contribution the
On Numbrino sales and being the from expect surgeries base of sales, and net competitive fewer pressured erosion a last with slower-than-anticipated be side, overall of competitor largely pricing due our to entering associated gross be we our crisis. Along recently our of compression our loss year, to elective fluphenazine. product we recent market, the performed COVID the portfolio, flip impacted to share by by with largest normal margin also of results expansion during the expect
of FY a of potential. lower to With the from be sales, expenses, regard to anticipate 'XX lopinavir normalization treatment operating we in our we expect significantly COVID-related Finally, benefited which year and coming SG&A initially versus of last plan cost the we result restructuring The completed, implemented reduction annualized $XX announced have in and largely plan been month. a the approximately savings expect million. as measures cost and
are our with longer-term While significant we see forecasting year mid- prospects profits, we on unchanged down to potential. growth a
our expected calls. been fluphenazine of then substantially. anticipated year. product And forecasted value we last always largest the contribution largest to to portfolio future previous we as last loss do the less Levothyroxine. the disciplined parade with year competition was have an from past Again, our significantly fluphenazine product, through will our our so like of and launch increased expectation our our our Additionally, cost thoughtful noting differentiated A aggressive decline demonstrated ability balance in just earnings to our successfully approach management fluphenazine, of manage structure, we of product, a reduced sheet,
the to billion $X belief that pipeline the products to company low similarly will So We to with remains by want detail ability in have XXs our exciting XXXX XXXX, our a margin in transform briefly also trajectory our growth John be in on still discuss a in our profit percentage our gross in place. the shortly. a fiscal I comment improving greater sheet. more to profile leverage. operating guidance due balance and expect
helped working $XXX of I over As improve at approximately more initiatives moment capital ago, to increase mentioned XX% our position a cash to XX, quarter. the June an million than our prior the raise
financial Meanwhile, proactively mature Loan ratios. use than Loan a that than years that more cash It's our more Having no that, Loan extend EBITDA. goal right that have to Our this of the time. a pay full two As, facility over down in November. us for our covenant said noting relatively of later monitor the maturities XXXX, at before a Term level remaining capital low to we year debt, we November Xx Bs and and to intend have Bs is plan evaluate remains which and mature options markets to our the in no to cost gross has time today. this in our worth adjusted portion notes, Nevertheless, pursue our is Term our and debt debt convertible underlying Term continue
to notably four obviously months fiscal as of products, the two new A product remains very Levothyroxine Levothyroxine current and the commenced first ahead we time not two large XXXX, marketing frame nearly years Regarding launched product opportunity, past product have Fluoxetine, agreement change already a associated launches. lucrative new full of we Levorphanol with including Lidocaine, tablets. although as again, that the the the us our original with in dynamics. strategic the market partner. given for In
launch not least focusing balance products fiscal plan this of the strong of possibly year. Note, but another evidenced eight tablets is four toward launch year-to-date, last launches quantity the XXXX, Sumatriptan to Levothyroxine posaconazole also the end the Nasal to our year fiscal at quality the we products fiscal and only year. our addition the on In of are Spray including by as of our launched now over
Turning business to development.
of value our portfolio. like DPI, expected the of works. in-license continue to the in number driving forward we exciting are busy which remains a other They team fluticasone announced, recently Our products opportunities
agreements our partnering through partners have are on been Vardenafil, we We extended collaborating successes. our are existing and terms. commercial also posaconazole successful ADVAIR all working on generic to to and The distribution demonstrated extend speak others. with extensions These
products Turning have partner that XX pending to FDA, so now another approved are more another development, our pipeline. We than products with and the XX launch. ANDAs or products, X plus at in including pending
of our are feedback Regarding meeting insulin glargine Lantus. on the product FDA US our glargine. provided the of with on with X, and Based to FDA on clinical and FDA, program biosimilar we clinical as spoke we on advancement product. the developing positive product, advancement guidance partnered the received CMC the so-called More specifically, the June the the biosimilar biosimilar a
this As a on study as multiple additional and development reminder, plant the and greater essentially conducted analogs for comparative the products new required multiple designed in capacity likely around already trial a is once fronts. at and markets. positive be study, previous of which new insulin constructed HEC, study for HEC insulin a demonstrate, with This FDA analytical insulin a producing site produce be at U.S. guidance similarity, two as will well-capitalized healthy and company has and it plant reviewed. larger trial one with FDA volunteer is insulin partner, volunteer much glargine expertise our we would on large healthy only is another compliance focused again, developing least be This glargine. same such approval. may completed the the Once
trials possibility months development First, our safety may such studies and certain not had efficacy plan. since time expected we development included required, several previous to are in the we be of save of and
are having related there cost to obviously the savings not to Second, extra significant studies. conduct
anticipated of worth internal to a billion for market to standard quite the We calendar study million. to could development competitors, volunteer biologic and license healthy next considering to track, projections, And planned than believe targeting an X various more the on the enrollment a we about If activities be XX% According fiscal based $XXX product launch U.S. given is IQVIA of of patient XXXX. is X $X sales pricing on possible in in market filed are analogs assumptions, share year. year just application remain our calendar XXXX. be begin
few As the X is to is expect and have our insulin different insulin expected we in the insulins By very after insulin and hundreds while It's versus see few of biosimilar, investment insulins dynamics insulin the Nordisk before, insulins. HEC, important in markets. of less market insulin tens approvals usage Such glargine introduce a the several regulated producing Novo outside tons other Lannett's time other and exceptional some are for be metric competitors we of are facilities the markets of insulins. regulatory smaller which products our applications. analog metric This measured the to have as Sanofi Eli large expertise have competitive biosimilar globally. will financial majors opportunity. those leverage advanced and a tens and expects market insulin additional we The is market for increasing. enter provides biopharmaceuticals, tons than companies. had kilograms Very has of like of glargine in necessary of we with likely developed situation support the U.S. biopharmaceutical to develop to product invested the opportunities Lilly, and this expect large facilities that can have insulin the intensity and in to such and partner for biosimilar been or insulin file filing development, product, technical as dedicated a few have of Lannett XXXX. U.S. much just commercial partner, tens non-insulin dollars as expertise note this one said produced Europe, Major in resources production. of material to Lannett the insulin players made worldwide BLA In is to companies contrast millions insulins
generic ADVAIR. to Turning
This the early interrupted this calendar late we were FDA submission track We an the net ANDA remain is intend the for pivotal ADVAIR for quality glargine, to one believe the the our and market pandemic, made FY in respiratory large of fiscal us. respiratory next note, launch Generic existing developing Meanwhile, we've on few we have Based companies XXXX. assumptions, substantial financial in year believe resources possible in-license on. our extend but progress on and relationships as PK we market. our focus Depending file to market on and have we And durable are of additional product by On anticipate have is potentially expertise products offering. identified we technical sales similar to and U.S. we year. restarted opportunity seen we to which expanding is year. standard have to inhaler and ones. some a and sales trials, growing, review another on new insulin related XXXX time, this a fiscal that product participate
legislation. sum U.S.-based legislation headquartered of drugs. should believe a we Finally, U.S.-based To is efforts emerge, medications bipartisan and positioned eventually pharmaceutical options large congressional to and engaged such see which purchasers tax are while to are U.S. manufacturer, seemingly that still government certain preferred generic benefit legislative Whatever frequently agencies, an rare status as support include to up. efforts are evolving, variety companies. Congress evaluating a of well extensive designed relief and/or suppliers from We we see to Lannett, of
Our fourth We products as quarter products. launch pressures fiscal continuing that as fiscal provided for expectations. well anticipated net exceeded sales and XXXX and reflects XXXX certain of key our competitive guidance adjusted pricing on the recent EPS new
a remaining debt We of covenant million pay $XX our in paid, month, more plan in balance annualized last just ratios. approximately little remaining a November. in began We our year Loan Levothyroxine estimated off cost our to We no reduction than Once supplier. A plan full has Term completed loss earlier have that a generate largely is to the since financial remarketing savings.
track with calendar sales that generic products insulin a may The ANDA durable expensively achieve the the filing our belief a anchor focused on progress following that than for billion we quickly build end for to the glargine year. on by FDA. $X the value. more biosimilar looking are positive Such for less ADVAIR of products development anticipated, originally we of can We and around meeting We pipeline of XXXX. is remain
I like that, I customers, their during the the and for efforts dedication to John? acknowledge hard challenging work and COVID over With our thank again I of Finally, management to times. teams suppliers, pandemic. would commendable their all employees for these during turn John. them call
